LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers

Nature Communications

Volumn 5, Issue , 2014, Pages

  Yu, Haiyang ^a   Yue, Xuetian ^a   Zhao, Yuhan ^a   Li, Xiaoyan ^a,b   Wu, Lihua ^a,c   Zhang, Cen ^a   Liu, Zhen ^a   Lin, Kevin ^a   Xu Monette, Zijun Y ^d   Young, Ken H ^d   Liu, Juan ^a   Shen, Zhiyuan ^a   Feng, Zhaohui ^a   Hu, Wenwei ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b SHANDONG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INHIBITOR OF DIFFERENTIATION 1; LEUKEMIA INHIBITORY FACTOR; PROTEIN MDM2; PROTEIN P53; STAT3 PROTEIN; ID1 PROTEIN, HUMAN; LIF PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

BLOOD; CANCER; DISABILITY; ENZYME ACTIVITY; GENE EXPRESSION; PROTEIN; TUMOR;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NEGATIVE FEEDBACK; PROTEIN DEGRADATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; XENOGRAFT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL AGING; CELL SURVIVAL; COHORT ANALYSIS; COLORECTAL TUMOR; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; MOUSE; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; CELL SURVIVAL; COHORT STUDIES; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LEUKEMIA INHIBITORY FACTOR; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84924252176     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6218     Document Type: Article

References (63)

1. Levine, A. J., Hu, W. & Feng, Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 13, 1027-1036 (2006).
2. Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413-431 (2009).
3. Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci. Publ. 247-270 (2004).
4. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
5. Hu, W. et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res. 67, 2757-2765 (2007).
6. Bond, G. L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004).
7. Harris, S. L. & Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908 (2005).
8. Wade, M. & Wahl, G. M. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol. Cancer Res. 7, 1-11 (2009).
9. Leng, R. P. et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791 (2003).
10. Li, J. et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet. 31, 133-134 (2002).
11. Duan, W. et al. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl Cancer Inst. 96, 1718-1721 (2004).
12. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
13. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
14. Iacopetta, B. TP53 mutation in colorectal cancer. Hum. Mutat. 21, 271-276 (2003).
15. Hwang, P. M. et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracilinduced apoptosis in colorectal cancer cells. Nat. Med. 7, 1111-1117 (2001).
16. Lowe, S. W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
17. Elsaleh, H. et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res. 7, 1343-1349 (2001).
18. Russo, A. et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 23, 7518-7528 (2005).
19. Metcalf, D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 21, 5-14 (2003).
20. Williams, R. L. et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336, 684-687 (1988).
21. Stewart, C. L. et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359, 76-79 (1992).
22. Takahashi, Y. et al. Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway. Mol. Endocrinol. 22, 1673-1681 (2008).
23. Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20 (2003).
24. Watanabe, S. et al. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 25, 2697-2707 (2006).
25. Hu, W., Feng, Z., Teresky, A. K. & Levine, A. J. p53 regulates maternal reproduction through LIF. Nature 450, 721-724 (2007).
26. Hu, W. The role of p53 gene family in reproduction. Cold Spring Harb. Perspect. Biol. 1, a001073 (2009).
27. Kang, H. J. et al. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc. Natl Acad. Sci. USA 106, 9761-9766 (2009).
28. Feng, Z. et al. Regulation of female reproduction by p53 and its family members. FASEB J. 25, 2245-2255 (2011).
29. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
30. Hui, C. M. et al. Id-1 promotes proliferation of p53-deficient esophageal cancer cells. Int. J. Cancer 119, 508-514 (2006).
31. Gadient, R. A. & Patterson, P. H. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 17, 127-137 (1999).
32. Lassmann, S. et al. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J. Clin. Pathol. 60, 173-179 (2007).
33. Lin, L. et al. STAT3 is necessary for proliferation and survival in colon cancerinitiating cells. Cancer Res. 71, 7226-7237 (2011).
34. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
35. Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102 (2009).
36. Niu, G. et al. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 25, 7432-7440 (2005).
37. Korchynskyi, O. & ten Dijke, P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J. Biol. Chem. 277, 4883-4891 (2002).
38. Lopez-Rovira, T., Chalaux, E., Massague, J., Rosa, J. L. & Ventura, F. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J. Biol. Chem. 277, 3176-3185 (2002).
39. Gautschi, O. et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 68, 2250-2258 (2008).
40. Tournay, O. & Benezra, R. Transcription of the dominant-negative helix-loophelix protein Id1 is regulated by a protein complex containing the immediateearly response gene Egr-1. Mol. Cell. Biol. 16, 2418-2430 (1996).
41. Phi, J. H. et al. Upregulation of SOX2, NOTCH1, and ID1 in supratentorial primitive neuroectodermal tumors: a distinct differentiation pattern from that of medulloblastomas. J. Neurosurg. Pediatrics 5, 608-614 (2010).
42. Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L. & Weintraub, H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59 (1990).
43. Lee, T. K. et al. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin. Cancer Res. 12, 6910-6919 (2006).
44. Ling, M. T. et al. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis 25, 517-525 (2004).
45. Ling, M. T. et al. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 22, 4498-4508 (2003).
46. Zigler, M. et al. Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res. 71, 3494-3504 (2011).
47. Fong, S., Debs, R. J. & Desprez, P. Y. Id genes and proteins as promising targets in cancer therapy. Trends Mol. Med. 10, 387-392 (2004).
48. Cheung, H. W., Ling, M. T., Tsao, S. W., Wong, Y. C. & Wang, X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25, 881-887 (2004).
49. Hu, H. et al. The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells. Oncol. Rep. 21, 1053-1059 (2009).
50. O'Brien, C. A. et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 21, 777-792 (2012).
51. Meteoglu, I., Meydan, N. & Erkus, M. Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy. J. Exp. Clin. Cancer Res. 27, 69 (2008).
52. Gearing, D. P. et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 6, 3995-4002 (1987).
53. Fitzgerald, J. S. et al. Leukemia inhibitory factor triggers activation of signal transducer and activator of transcription 3, proliferation, invasiveness, and altered protease expression in choriocarcinoma cells. Int. J. Biochem. Cell Biol. 37, 2284-2296 (2005).
54. Li, X. et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget 5, 788-801 (2014).
55. Liu, S. C. et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J. Clin. Invest. 123, 5269-5283 (2013).
56. Maruta, S. et al. A role for leukemia inhibitory factor in melanoma-induced bone metastasis. Clin. Exp. Metastasis 26, 133-141 (2009).
57. Wysoczynski, M. et al. Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas. Cancer Res. 67, 2131-2140 (2007).
58. Hillion, J. et al. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res. 68, 10121-10127 (2008).
59. Zhang, C. et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl Acad. Sci. USA 108, 16259-16264 (2011).
60. Zheng, T. et al. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat. Commun. 4, 2996 (2013).
61. Smith, J. J. et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138, 958-968 (2010).
62. Freeman, T. J. et al. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology 142, 562-571 e562 (2012).
63. Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).